The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ACLARIS THERAPEUTICS INC COM 00461U105   133,387 19,473 SH   SOLE   19,473 0 0
ALLAKOS INC COM 01671P100   111,978 49,329 SH   SOLE   49,329 0 0
APOGEE THERAPEUTICS INC COM 03770N101   265,653 12,472 SH   SOLE   12,472 0 0
COMPASS THERAPEUTICS INC COM 20454B104   170,942 86,773 SH   SOLE   86,773 0 0
ELEVATION ONCOLOGY INC COM 28623U101   14,453 21,813 SH   SOLE   21,813 0 0
MOLECULAR TEMPLATES INC COM NEW 608550208   864,993 136,866 SH   SOLE   136,866 0 0
REZOLUTE INC COM NEW 76200L309   1,741,036 1,318,967 SH   SOLE   1,318,967 0 0
SAVARA INC COM 805111101   12,525,416 3,313,602 SH   SOLE   3,313,602 0 0
XERIS BIOPHARMA HOLDINGS INC COM 98422E103   10,493,971 5,641,920 SH   SOLE   5,641,920 0 0